Please assess the completion status of the following clinical trial:

Trial Title: A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have a BMI of 18.0 to 40.0 kg/m2, inclusive~* Agree to use an acceptable method of contraception for the duration of the study~* Have an MDD primary diagnosis~* Have no more than 2 inadequate responses to antidepressant therapy (ADT) in the current Major Depressive Episode (MDE)~* Additional criteria may apply~Exclusion Criteria:~* Have a current primary Axis-I disorder other than MDD~* Have used opioid agonists (eg, codeine, oxycodone, tramadol, morphine) or opioid antagonists (eg, naloxone, naltrexone) within 14 days~* Have received electroconvulsive therapy treatment within the last 2 years or received more than one course of electroconvulsive treatment during their lifetime~* Have attempted suicide within the past 2 years~* Have a positive test for drugs of abuse~* Are pregnant, planning to become pregnant, or breastfeeding~* Have a history of intolerance, allergy, or hypersensitivity to buprenorphine or opioid antagonists (eg, naltrexone, naloxone)~* Have had a significant blood loss or blood donation within 60 days~* Additional criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- High Dose (Type: EXPERIMENTAL): None
- Low Dose (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).